'People's Hero' – Chen Wei
发布日期:2020-10-15 浏览次数:

国庆期间,兰溪六位耄耋之年的老教师

收到了一份特殊的礼物

荣获“人民英雄”国家荣誉称号的陈薇

回到了家乡兰溪

短短两天时间

她专门抽出一天时间看望了

六位初高中时代的恩师

送上了满满的节日祝福

这让这些亲眼目睹她成长的老师们激动不已




Chen Wei

陈薇(中国工程院院士)

陈薇,1966年2月生,浙江兰溪人,中共党员,军事科学院军事医学研究院生物工程研究所所长、研究员。她长期致力于生物危害防控研究。

Chen Wei was born in Lanxi, a county-level city in Jinhua, East China's Zhejiang province, in February 1966. She is a member of the Communist Party of China as well as director and researcher at the Institute of Military Medicine under the Academy of Military Sciences. She is a long-time researcher of biohazard prevention and control.


抗击非典时,研制出我军首个SARS预防生物新药“重组人干扰素ω”;汶川抗震时,作为“国家减灾委科技部抗震救灾专家委员会”卫生防疫组组长,为“大灾之后无大疫”作出重要贡献;赴非洲抗击埃博拉疫情,率团队研发出全球首个获批新药证书的埃博拉疫苗,突破了世界性难题。


如今,她奋战在战“疫”一线,成功研制出重组新冠疫苗,并展开临床试验。

Currently, she is aiding in efforts to overcome the epidemic. Her team has created a COVID-19 vaccine and pushed forward clinical trials. 


9月8日,在全国抗击新冠肺炎疫情表彰大会上,陈薇获颁“人民英雄”国家荣誉称号奖章。

Chen was awarded the "People's Hero" national honorary title at a meeting commending role models in China's fight against the COVID-19 epidemic on Sept 8. 



2020年新年伊始,一场突如其来的新冠肺炎疫情暴发。面对百年不遇的重大突发公共卫生事件,科学家、医护人员、解放军指战员从祖国的四面八方紧急驰援武汉,在疫情防控的最前线打响了一场生命保卫战。


陈薇就是这群“最美逆行者”中的一员。由她领衔的军事医学专家组在武汉连续奋战113天,以最优设计、最快速度、最短时间推出了一系列重大成果,以实际行动回应了人民期盼,展现了中国战“疫”的“硬核”实力。


这是一个个值得铭记的闪光时刻——


3月16日

陈薇带领科研团队研制的新冠病毒疫苗,获批正式进入临床试验。

On March 16, the subunit vaccine against COVID-19 created by Chen's team was approved for clinical trials.


4月10日

完成疫苗一期临床试验接种的108位志愿者,全部结束集中医学观察,健康状况良好。

On April 10, the potential vaccine for COVID-19 appeared safe and able to generate an immune response after phase-1 clinical trials including 108 volunteers.


4月12日

该疫苗开展二期临床试验,成为当时全球唯一进入二期临床试验的新冠病毒疫苗,相关试验结果已在国际学术期刊《柳叶刀》上在线发表。

On April 12, the second phase of clinical trials started. It was the only COVID-19 vaccine in the world that had entered second-phase clinical trials at that time. The experimental results have been published on The Lancet, an international academic journal. 


8月11日

该疫苗获得国家专利,成为国内首个进入临床获得专利权的新冠疫苗。

On Aug 11, the vaccine was granted a national patent. It became the first COVID-19 vaccine to start clinical trials and obtain patent rights in China.


9月7日

陈薇表示,团队研发的重组新冠疫苗,对已经发生变异的新冠病毒能够完全覆盖。从目前来看,年产3亿的目标是可以实现的,他们正在努力扩大产能。

On Sept 7, Chen said that the recombinant vaccine developed by her team is effective against all mutations of the novel coronavirus. China can currently produce 300 million doses of the recombinant COVID-19 vaccine per year and will further expand its capacity.



2月26日第一批疫苗在生产线下线的那天,正好是陈薇的生日。

On Feb 26, Chen's birthday, the first batch of vaccine developed by her team went on production line.


收到领导和朋友们给她发的祝福,陈薇当时回复了8个字:“除了胜利,别无选择!(No choice but success)



END



来源:金华新闻、人民日报、求是网、东方IC


编辑:薛心仪

审核:刘秀红、秦继蓉

监制:施力维






Produced By 大汉网络 大汉版通发布系统